Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

Journal of Clinical Hypertension

Volumn 18, Issue 4, 2016, Pages 342-351

  Zhang, Xiaodan ^a   Zhao, Qingyu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; METOPROLOL; MOEXIPRIL; PLACEBO; PRAZOSIN; PROPRANOLOL; THIAZIDE DIURETIC AGENT; VERAPAMIL; GLUCOSE BLOOD LEVEL;

ARTICLE; BODY MASS; CARDIOVASCULAR PARAMETERS; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; META ANALYSIS; METABOLIC PARAMETERS; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; GLUCOSE INTOLERANCE; METABOLISM; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; BLOOD PRESSURE; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84945156248     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12679     Document Type: Article

References (50)

1. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
2. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
4. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-207.
5. Rastogi D, Pelter MA, Deamer RL. Evaluations of hospitalizations associated with thiazide-associated hyponatremia. J Clin Hypertens (Greenwich). 2012;14:158-164.
6. Vandell AG, McDonough CW, Gong Y, et al. Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study. J Intern Med. 2014;276:486-497.
7. Deshmukh M, Lee HW, McFarlane SI, et al. Antihypertensive medications and their effects on lipid metabolism. Curr Diab Rep. 2008;8:214-220.
8. Higgins J, Green S. Cochrane handbook for systematic reviews of intervention 5.1.0 (2011) Cochrane Collaboration. http://handbook.cochrane.org. Accessed October 16, 2014.
9. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
10. Musini VM, Nazer M, Bassett K, et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014;5:CD003824.
11. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med. 1994;154:737-743.
12. Reisin E, Weir MR, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension. 1997;30:140-145.
13. Jounela AJ, Lilja M, Lumme J, et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press. 1994;3:231-235.
14. Fuenmayor NT, Moreira E, de los Rios V, et al. Relations between fasting serum insulin, glucose, and dihydroepiandrosterone-sulfate concentrations in obese patients with hypertension: short-term effects of antihypertensive drugs. J Cardiovasc Pharmacol 1997;30:523-527.
15. Helgeland A, Leren P, Foss OP, et al. Serum glucose levels during long-term observation of treated and untreated men with mild hypertension. The Oslo study. Am J Med. 1984;76:802-805.
16. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158:741-751.
17. Vardan S, Mehrotra KG, Mookherjee S, et al. Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. JAMA. 1987;258:484-488.
18. Carlsen JE, Køber L, Torp-Pedersen C, et al. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990;300:975-978.
19. Pool PE, Applegate WB, Woehler T, et al. A randomized, controlled trial comparing diltiazem, hydrochlorothiazide, and their combination in the therapy of essential hypertension. Pharmacotherapy. 1993;13:487-493.
20. Siegel D, Saliba P, Haffner S. Glucose and insulin levels during diuretic therapy in hypertensive men. Hypertension. 1994;23:688-694.
21. Mersey J, D'Hemecourt P, Blaze K. Once-daily fixed combination of captopril and hydrochlorothiazide as first line therapy for mild to moderate hypertension. Curr Ther Res Clin Exp. 1993;53:502-512.
22. Fiddes R, Blumenthal J, Dawson JE, et al. Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension. J Hum Hypertens. 1997;11:239-244.
23. Hall WD, Weber MA, Ferdinand K, et al. Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension. J Hum Hypertens. 1994;8:571-575.
24. Calvo C, Gude F, Abellan J, et al. A comparative evaluation of amlodipine and hydrochlorothiazide as monotherapy in the treatment of isolated systolic hypertension in the elderly. Clin Drug Invest. 2000;19:317-326.
25. Pareek A, Karnik N, Salagre SB, et al. Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study. Curr Med Res Opin. 2008;24:1771-1779.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-2997.
27. Piecha G, Adamczak M, Chudek J, et al. Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res. 2007;30:187-194.
28. Jansen RW, Van Lier HJ, Hoefnagels WH. Nitrendipine versus hydrochlorothiazide in hypertensive patients over 70 years of age. Clin Pharmacol Ther. 1989;45:291-298.
29. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
30. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol. 1985;7(Suppl 1):S52-S55.
31. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761-1769.
32. Zappe DH, Sowers JR, Hsueh WA, et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2008;10:894-903.
33. Stimpel M, Koch B, Oparil S. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology. 1998;89:271-276.
34. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension. 1985;7:1008-1016.
35. Berglund G, Andersson O. Beta-blockers or diuretics in hypertension? A 6 year follow-up of blood pressure and metabolic side effects. Lancet. 1981;1:744-747.
36. Alderman MH, Davis TK, Carroll L. Initial antihypertensive therapy. Comparison of prazosin and hydrochlorothiazide. Am J Med. 1986;80:120-125.
37. Verdecchia P, Angeli F, Reboldi GP, et al. New-onset diabetes in treated hypertensive patients. Curr Hypertens Rep. 2005;7:174-179.
38. Barzilay JI, Davis BR, Whelton PK. The glycemic effects of antihypertensive medications. Curr Hypertens Rep. 2014;16:410.
39. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29-35.
40. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48:219-224.
41. Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of candesartan (MEDICA) study. Hypertension. 2008;52:1030-1037.
42. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999;17:151-183.
43. Harper R, Ennis CN, Sheridan B, et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309:226-230.
44. Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med. 1996;101:83S-92S.
45. Karnes JH, Gong Y, Arwood MJ, et al. Alteration in fasting glucose after prolong treatment with a thiazide diuretic. Diabetes Res Clin Pract. 2014;104:363-369.
46. Hirst JA, Farmer AJ, Feakins BG, et al. Quantifying the effects of diuretics and beta-blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;79:733-743.
47. Fujiwara W, Izawa H, Ukai G, et al. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart Vessels. 2013;28:316-322.
48. Mukete BN, Rosendorff C. Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium - a meta-analysis. J Am Soc Hypertens. 2013;7:454-466.
49. Carter BL, Einhorn PT, Brands M, et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension. 2008;52:30-36.
50. Aksnes TA, Kjeldsen SE, Rostrup M, et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension. 2007;50:467-473.